FFEA Stock Overview
Researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Faes Farma, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.45 |
| 52 Week High | €3.79 |
| 52 Week Low | €2.85 |
| Beta | 0.51 |
| 1 Month Change | 0.58% |
| 3 Month Change | -4.83% |
| 1 Year Change | 8.85% |
| 3 Year Change | 2.65% |
| 5 Year Change | -34.63% |
| Change since IPO | -56.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| FFEA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 1.6% | 1.2% | 1.2% |
| 1Y | 8.8% | -14.1% | 10.1% |
Return vs Industry: FFEA exceeded the German Pharmaceuticals industry which returned -15% over the past year.
Return vs Market: FFEA matched the German Market which returned 9.4% over the past year.
Price Volatility
| FFEA volatility | |
|---|---|
| FFEA Average Weekly Movement | 3.2% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: FFEA has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: FFEA's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1933 | 1,762 | n/a | faesfarma.com |
Faes Farma, S.A., researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials worldwide. It operates through Pharmaceutical and Healthcare Specialties; Animal Nutrition and Health; and Pharmaceutical Raw Materials segments. It offers products for various therapeutic areas.
Faes Farma, S.A. Fundamentals Summary
| FFEA fundamental statistics | |
|---|---|
| Market cap | €1.08b |
| Earnings (TTM) | €97.59m |
| Revenue (TTM) | €504.04m |
11.1x
P/E Ratio2.1x
P/S RatioIs FFEA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FFEA income statement (TTM) | |
|---|---|
| Revenue | €504.04m |
| Cost of Revenue | €169.88m |
| Gross Profit | €334.16m |
| Other Expenses | €236.57m |
| Earnings | €97.59m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.31 |
| Gross Margin | 66.30% |
| Net Profit Margin | 19.36% |
| Debt/Equity Ratio | 6.9% |
How did FFEA perform over the long term?
See historical performance and comparisonDividends
4.5%
Current Dividend Yield50%
Payout RatioDoes FFEA pay a reliable dividends?
See FFEA dividend history and benchmarks| Faes Farma dividend dates | |
|---|---|
| Ex Dividend Date | Jan 09 2025 |
| Dividend Pay Date | Jan 13 2025 |
| Days until Ex dividend | 2 days |
| Days until Dividend pay date | 2 days |
Does FFEA pay a reliable dividends?
See FFEA dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/09 20:49 |
| End of Day Share Price | 2025/01/09 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Faes Farma, S.A. is covered by 14 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Álvaro Arístegui Echevarría | Ahorro Corporación |
| Kamla Singh | AlphaValue |
| Guilherme Sampaio | Banco BPI, S.A. |